Related Experiment Video
Updated: May 10, 2026
Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent
Published on: May 8, 2017
Radiolabeled COX-2 inhibitors for non-invasive visualization of COX-2 expression and activity--a critical update
Markus Laube1, Torsten Kniess, Jens Pietzsch
1Department Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstrasse 400, 01328 Dresden, Germany. m.laube@hzdr.de
Abstract:
Cyclooxygenase-2 (COX-2) is a key player in inflammation. Its overexpression is directly associated with various inflammatory diseases and, additionally, with several processes of carcinogenesis. The development of new selective COX-2 inhibitors (COXIBs) for use in cancer treatment is in the focus of the medicinal chemistry research field. For this purpose, a set of methods is available to determine COX-2 expression and activity in vitro and ex vivo but it is still a problem to functionally characterize COX-2 in vivo. This review focusses on imaging agents targeting COX-2 which have been developed for positron emission tomography (PET) and single photon emission computed tomography (SPECT) since 2005. The literature reveals that different radiochemical methods are available to synthesize COXIBs radiolabeled with fluorine-18, carbon-11, and isotopes of radioiodine. Unfortunately, most of the compounds tested did not show sufficient stability in vivo due to de[¹⁸F]fluorination or de[¹¹C]methylation or they failed to bind specifically in the target region. So, suitable stability in vivo, matching lipophilicity for the target compartment and both high affinity and selectivity for COX-2 were identified as prominent criteria for radiotracer development. Up to now, it is not clear what approach and which model is the most suited to evaluate COX-2 targeting imaging agents in vivo. However, for proof of principle it has been shown that some radiolabeled compounds can bind specifically in COX-2 overexpressing tissue which gives hope for future work in this field.
Insights
Developing new imaging agents for cyclooxygenase-2 (COX-2) is crucial for cancer treatment. While radiolabeled COX-2 inhibitors show promise, in vivo stability and target specificity remain key challenges for effective cancer imaging.
Area of Science:
- Medicinal Chemistry
- Molecular Imaging
- Oncology
Background:
- Cyclooxygenase-2 (COX-2) is implicated in inflammation and cancer development.
- Selective COX-2 inhibitors (COXIBs) are a focus for cancer therapy research.
- In vivo functional characterization of COX-2 remains challenging.
Observation:
- This review examines COX-2 targeting imaging agents developed for PET and SPECT since 2005.
- Radiolabeling methods using fluorine-18, carbon-11, and radioiodine are available for COXIB synthesis.
- Many developed radiotracers exhibit insufficient in vivo stability or lack target specificity.
Findings:
- Key criteria for successful radiotracer development include in vivo stability, appropriate lipophilicity, and high COX-2 affinity/selectivity.
- Despite challenges, some radiolabeled compounds have demonstrated specific binding in COX-2 overexpressing tissues.
- Optimal in vivo evaluation models for COX-2 imaging agents are yet to be established.
Implications:
- Successful development of COX-2 imaging agents could significantly advance cancer diagnosis and treatment monitoring.
- Further research is needed to overcome stability and specificity issues in radiotracer design.
- Targeted molecular imaging holds potential for personalized cancer therapy strategies.
